MAS825 + Standard of Care (SoC)

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

COVID-19 Pneumonia, Impaired Respiratory Function

Conditions

COVID-19 Pneumonia, Impaired Respiratory Function

Trial Timeline

Jun 11, 2020 → Apr 21, 2021

NCT ID

NCT04382651

About MAS825 + Standard of Care (SoC)

MAS825 + Standard of Care (SoC) is a phase 2 stage product being developed by Novartis for COVID-19 Pneumonia, Impaired Respiratory Function. The current trial status is completed. This product is registered under clinical trial identifier NCT04382651. Target conditions include COVID-19 Pneumonia, Impaired Respiratory Function.

What happened to similar drugs?

7 of 20 similar drugs in COVID-19 Pneumonia, Impaired Respiratory Function were approved

Approved (7) Terminated (4) Active (11)

✅mRNA-1283.251 Variant-containing FormulationModernaApproved

✅AZD1222AstraZenecaApproved

✅Rivaroxaban 10 mgBayerApproved

✅Novavax COVID-19 vaccine (2023-2024 formula XBB containing) + Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)NovavaxApproved

✅protein subunit: Novavax COVID-19 vaccine + Pfizer mRNA COVID-19 vaccineNovavaxApproved

✅NVX-CoV2705 + PlaceboNovavaxApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04382651	Phase 2	Completed	Jun 11, 2020	Apr 21, 2021	COVID-19 Pneumonia, Impaired Respiratory Function

Competing Products

20 competing products in COVID-19 Pneumonia, Impaired Respiratory Function

See all competitors

Product	Company	Stage	Hype Score
mRNA-1283.251 Variant-containing Formulation	Moderna	Approved	0
mRNA-1283.222	Moderna	Phase 3	0
COVID-19 Vaccine	Moderna	Preclinical	0
mRNA-1083	Moderna	Phase 3	0
SPIKEVAX (mRNA-1273)	Moderna	Preclinical	0
Moderna COVID-19 Vaccine	Moderna	Preclinical	0
Gam-COVID-Vac	Dr. Reddy's Laboratories	Phase 2/3	31
Human COVID-19 immunoglobulin (pH4) for intravenous injection + Placebo	Sinopharm	Phase 2	31
Mavrilimumab + Placebos	Kiniksa Pharmaceuticals	Phase 2	29
Gimsilumab + Placebo	Roivant Sciences	Phase 2	32
Icosapent ethyl	Amarin Corporation	Phase 2	25
Bamlanivimab + Placebo + Etesevimab	Eli Lilly	Phase 3	40
Infliximab	Celltrion	Phase 2	35
CT-P63 and CT-P66 / Placebo	Celltrion	Phase 3	32
Enzalutamide Pill	Astellas Pharma	Phase 2	27
S-892216 + Placebo	Shionogi	Phase 2	35
S-892216 + Carbamazepine	Shionogi	Phase 1	29
FOY-305 + Placebo	Ono Pharmaceutical	Phase 3	40
Desidustat	Zydus Lifesciences	Phase 2	35
LY3819253 + Placebo	Eli Lilly	Phase 1	29